Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084253 · ClinicalTrials.gov registry record · Phase 4
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
A Phase 4 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00084253: Completed Phase 4 study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00084253 is a Phase 4 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084253, a Phase 4 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV) works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine to slow or stop the progression of HIV infection in patients who have never used anti-HIV drugs.
Conditions Studied
Interventions
- DRUG Atazanavir/ Stavidine / Lamivudine
- DRUG Atazanavir-Ritonavir/ Stavidine / Lamivudine
Study Locations (1)
New Jersey
- Various locations within the US - Call For Information
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-06 |
| Phase | Phase 4 |
What the finished NCT00084253 record still lists
NCT00084253 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Atazanavir/ Stavidine / Lamivudine is the first listed.
NCT00084253 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00084253 about?
NCT00084253 is a clinical study titled "Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients". The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV) works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine to slow or stop the progression of HIV infection in patients who have never used anti-HIV drugs.
What is the current status of trial NCT00084253?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2004-06.
What conditions does trial NCT00084253 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00084253?
The interventions under investigation include: Atazanavir/ Stavidine / Lamivudine (DRUG), Atazanavir-Ritonavir/ Stavidine / Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00084253?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00084253 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00084253's enrollment target sits among peer trials
200 171st of 542 higher than 362 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia